Product Overview - The company has 26 products listed in the National Medical Insurance Directory, 10 in the National Essential Medicines List, 21 OTC products, and 13 exclusive products [2] - Key products include Kuntai Capsule, Kushi Gel, Ningpitai Capsule, and Xia Ku Cao Oral Liquid, with Kuntai Capsule being a patented product and the only traditional Chinese medicine for improving ovarian function [2][3] Growth Strategies - The company focuses on modern traditional Chinese medicine, targeting women's health, urinary system health, and chronic diseases, while also covering elderly and pediatric medications [3] - Plans to enhance the OTC market presence and implement an integrated online and offline marketing strategy [3] - Aims to establish a cluster of patented traditional Chinese medicine products and become a leading brand in specific therapeutic areas within 2-3 years [3] Research and Development - The company has established three R&D bases and is working on new drug innovations, including three products that have completed Phase III clinical trials [5][6] - Ongoing research includes classic traditional Chinese medicine formulas and clinical studies for key products [5][6] Market Position - The company ranks highly in the gynecology and urinary system sectors, with Kuntai Capsule ranked second in 2018 and recognized in various clinical value rankings [4][5] - OTC sales account for approximately 30% of total revenue [5] Financial Performance - The sales expense ratio for 2021 was 48.65%, focusing on professional academic promotion and OTC brand promotion [5] Future Plans - The company plans to accelerate the application for market approval for new drugs expected to be submitted before 2023 [6] - It is also exploring potential mergers and acquisitions to enhance its market position [6] Brand Development - The "Heyan" brand for women's health management is being promoted in four provinces, with advertising campaigns launched in various media [7][8]

编号：2022-014 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-024 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |-----------------------|--------------------------------------------------------------------------------------|------------------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------|----------| | | □√特定对象调研 □√分析师会议 | | | | | | 投资者关系活 | □媒体采访 □业绩说明会 | | | | | | 动类别 | □新闻发布会 | | □路 ...

编号：2022-017 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活 \n动类别 | □特定对象调研 □√分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 \n□现场参观 \n□√其他（电话会议） | □路演活动 | | | | 山西证券、华夏基金、光大控股、浦银安盛、融通基金、方正证券、红土 | | 参与单位名称 | 国际、信诚 ...

编号：2022-016 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------| | | □特定对象调研 □√分析师会议 | | | 投资者关系活 | □媒体采访 | □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □√其他（线上会议） | | | 参与单位名称 | | 通过平安证券线上会议系统参会：万家基金、量度资本、世诚资产、中信 | | 及人员姓名 | | 期货、中金资管、华泰资管、华泰联合、平安证券。 通过公司线上会议系统参会：长城基金、西部证券 ...

编号：2022-018 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-019 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活 \n动类别 | □新闻发布会 \n□现场参观 \n□√其他（电话、线上会议） | □特定对象调研 □√分析师会议 \n□媒体采访 □业绩说明会 \n□路演活动 | | 参与单位名称 | | 信诚基金、泰信基金、浦银安盛基金、银河基金、建信基金、银华基金、 华夏久盈基金、申万菱信基金、华安证券、开源证券、民生证券、山西证券 | | | | | | 时间 | 2022 年 7 月 ...

编号：2022-020 证券代码：002873 证券简称：新天药业 债券代码：128091 债券简称：新天转债 贵阳新天药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □√分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活 | □新闻发布会 | □路演活动 | | 动类别 | □现场参观 | | | | □√其他（电话、线上会议） | | | | | 中国人保、中信资管、中信保诚、中信期货、 ...

Group 1: Company Overview - Guizhou Xintian Pharmaceutical Co., Ltd. is listed under stock code 002873 and bond code 128091 [1] - The investor relations activity took place on November 10, 2022, in Shanghai [2] Group 2: Market Strategy - The company aims to ensure the growth of its leading products through clinical efficacy-driven marketing strategies [2][3] - Key strategies include optimizing marketing structure, enhancing brand promotion, and expanding market channels, particularly in lower-tier markets [3][4] Group 3: Research and Development Plans - The company focuses on two main areas: deepening expertise in gynecology and monitoring long-term market value [3] - Plans to increase R&D budget significantly in the coming year, with ongoing projects in innovative Chinese medicine, formula granules, and classic prescriptions [3][4] - The company has completed clinical trials for three innovative drugs and plans to apply for market approval in 2023 [3] Group 4: Production and Cost Management - The company has implemented smart manufacturing solutions to reduce production and labor costs, aiming for an annual output value exceeding 3 billion yuan [5] - New intelligent production lines and warehouses are expected to enhance efficiency and cost control [5] Group 5: Employee Incentives - The company plans to continue stock incentive programs for core positions to align employee growth with corporate development [5] - Emphasis on talent acquisition and internal performance evaluation to foster a motivated workforce [5]

Group 1: Company Performance - In the first half of 2022, the company achieved revenue of 525 million CNY, a year-on-year increase of 15.53% [3] - Net profit reached 57 million CNY, reflecting a year-on-year growth of 22.65% [3] - The company maintained operational stability despite challenges posed by the pandemic [3] Group 2: Strategic Response to Pandemic - The company adjusted inventory levels in anticipation of potential pandemic impacts, ensuring sufficient stock to meet demand [2] - Logistics channels were prioritized, with green transport corridors established to facilitate timely distribution [2] - Production schedules were adapted to quickly restore inventory levels during the pandemic [2] Group 3: Future Growth Strategy - The company is focused on a five-year strategic plan, with 2022-2023 being a critical overlap period for its second "three-year plan" [3] - Emphasis on sustainable growth through optimizing existing business and exploring new market opportunities [4] - The company aims to leverage its established product lines and market presence to achieve its "three-year doubling" business goal [4] Group 4: Marketing and Sales Development - The marketing team has been professionalized, with a focus on regional recruitment and specialized training [5] - The company has established long-term relationships with over 1,400 hospitals and 85,000 pharmacies nationwide [5] - The OTC product coverage includes over 800 chain pharmacies, enhancing market penetration [5] Group 5: Product Development and Innovation - The company is advancing three new drug applications, with expectations to submit for market approval in 2023 [4] - The "He Yan" brand, particularly the He Yan Kun Tai capsule, is positioned as a key product in the OTC market [6] - Marketing efforts for the He Yan brand include targeted advertising and promotional activities across various platforms [6]